Is Bloom Gone From Rosy ANDA Approvals Figures?
Executive Summary
US FDA sets a new monthly record for full approvals, but industry group argues that approvals alone aren't creating more generic competition in the market.
You may also be interested in...
FDA Reports Millions In Unpaid GDUFA Fees
The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.
US FDA Reports Millions In Unpaid GDUFA Program Fees
The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.
Generic Industry Wants US FDA To Consider Allowing Foreign Reference Products For ANDAs
If agency adopts policy, it might obviate the need for the CREATES Act. Biosimilars already enjoy a degree flexibility of on the source of reference material that generic sponsors want extended to the less complicated small molecule drugs.